US-based pharmaceutical company Merck has received US Food and Drug Administration (FDA) approval for Janumet XR, its new type 2 diabetes treatment.

Janumet XR combines sitagliptin, the active component of Januvia, with extended-release metformin in order to provide a once-daily treatment option for patients needing to control their blood sugar.

The drug received approval based upon the results of a clinical bioequivalence study, which demonstrated that the use of Janumet XR was equivalent to co-administration of corresponding doses of sitagliptin and metformin HCI extended-release.

Merck Diabetes and Endocrinology vice president, Barry Goldstein, said: "This is important because many patients with type 2 diabetes require treatment with multiple drugs to maintain blood sugar control, and Janumet XR is a new option to help more patients get to their glucose goals."

The drug will come with a boxed warning for lactic acidosis, a rare complication that can occur due to metformin accumulation.

Janumet XR has also not been studied in patients with a history of pancreatitis, and it is not yet known whether patients with a history of the illness are at an increased risk of developing pancreatitis whilst using the drug.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.